<p>Krilogy Financial LLC 在第二季度增持了 CRISPR Therapeutics AG（纳斯达克股票代码：CRSP）的持股，增幅达到 92.9%，根据该公司最近向证券交易委员会披露的信息。该公司在该时期购入额外的 10,050 股后，持有该公司股票 20,872 股。Krilogy Financial LLC 在最近一个季度结束时持有的 CRISPR Therapeutics 股票价值 1,127,000 美元。</p>
<p>获取 <strong>CRISPR Therapeutics</strong> 警报：</p>
<ul>
<li>3 家股价下跌的制药公司，有望迎来价格上涨的催化剂</li>
</ul>
<p>其他许多机构投资者最近也调整了他们对该公司的持股。Nordea Investment Management AB 在第一季度增持了 CRISPR Therapeutics 的持股，增幅为 40.8%。现在，Nordea Investment Management AB 持有该公司 148,700 股，价值 10,305,000 美元，上季度购入了 43,100 股。Congress Asset Management Co. MA 在第一季度增持了 CRISPR Therapeutics 的股份，增幅为 60.3%。现在，Congress Asset Management Co. MA 持有该公司 64,605 股，价值 4,403,000 美元，上季度购入了 24,303 股。PBCay One RSC Ltd 在第四季度购入了价值 10,329,000 美元的 CRISPR Therapeutics 新头寸。Cetera Investment Advisers 在第一季度将其对 CRISPR Therapeutics 的持股增加了 451.3%。Cetera Investment Advisers 现在持有该公司 34,100 股，价值 2,324,000 美元，上季度购入了 27,915 股。最后，CWM LLC 在第二季度将其对 CRISPR Therapeutics 的持股增加了 11,871.1%。CWM LLC 现在持有该公司 22,386 股，价值 1,209,000 美元，上季度购入了 22,199 股。目前，69.20% 的股份由对冲基金和其他机构投资者持有。</p>
<h2>分析师设定新的价格目标</h2>
<p>一些分析师对该公司发表了意见。Robert W. Baird 将 CRISPR Therapeutics 的价格目标从 46.00 美元提高到 52.00 美元，并在 5 月 9 日星期四的研究报告中给予该公司 “中性” 评级。Rodman &amp; Renshaw 在 8 月 2 日星期五对 CRISPR Therapeutics 的股票进行了覆盖。他们为该公司设定了 “买入” 评级和 90.00 美元的价格目标。Needham &amp; Company LLC 将 CRISPR Therapeutics 的目标价从 88.00 美元降至 84.00 美元，并在 8 月 6 日星期二的研究报告中为该公司设定了 “买入” 评级。巴克莱将 CRISPR Therapeutics 的目标价从 67.00 美元降至 59.00 美元，并在 8 月 6 日星期二的研究报告中为该股设定了 “等权重” 评级。最后，Guggenheim 在 6 月 28 日星期五的研究报告中重申了对 CRISPR Therapeutics 的 “中性” 评级。三位股票研究分析师给予该股 “卖出” 评级，八位给予 “持有” 评级，九位给予 “买入” 评级。根据 MarketBeat.com 的数据，该股目前的共识评级为 “持有”，平均目标价为 75.63 美元。</p>
<p><strong>阅读我们对 CRSP 的最新分析</strong></p>
<h2>CRISPR Therapeutics 股价表现</h2>
<p>CRSP 股票周三交易时上涨 0.92 美元，报价 49.99 美元。该股交易量为 1,108,313 股，相比平均交易量 1,573,917 股有所下降。该公司的市值为 42.5 亿美元，市盈率为-18.17，贝塔系数为 1.70。该股的五十日移动平均价格为 55.02 美元，两百日移动平均价格为 61.96 美元。CRISPR Therapeutics AG 的 52 周最低价为 37.55 美元，最高价为 91.10 美元。</p>
<p>CRISPR Therapeutics（纳斯达克股票代码：CRSP - 获取免费报告）于 8 月 5 日星期一发布了季度财报。该公司报告称，该季度每股收益（EPS）为-1.49 美元，低于市场预期的-1.43 美元。该季度业务收入为 520 万美元，而分析师预计为 12.31 亿美元。与去年同期相比，该季度业务收入下降了 99.3%。分析师预计，CRISPR Therapeutics AG 在本财年将实现-5.52 美元的每股收益。</p>
<h2>内部人员活动</h2>
<p>另外，首席运营官 Julianne Bruno 于 6 月 21 日星期五出售了 3,366 股 CRISPR Therapeutics 股票。这些股票的平均价格为 56.09 美元，总交易额为 188,798.94 美元。在此次交易后，首席运营官现在持有公司 6,745 股，价值 378,327.05 美元。该交易已在提交给证券交易委员会的文件中披露，可在此链接处查看。内部人员持有该公司的股份占公司股份的 4.10%。</p>
<h2>CRISPR Therapeutics 简介（免费报告）</h2>
<p>CRISPR Therapeutics 是一家专注于利用其专有的 CRISPR/Cas9 平台开发用于治疗严重疾病的转型基因药物的基因编辑公司。CRISPR/Cas9 是一种革命性的基因编辑技术，可以对基因组 DNA 进行精确、定向的改变。CRISPR Therapeutics 已在包括血红蛋白病、肿瘤学、再生医学和罕见疾病在内的广泛疾病领域建立了治疗项目组合。</p>
<h2>另请参阅</h2>
<ul>
<li>我们喜欢的五只股票，比 CRISPR Therapeutics 更好</li>
<li>交易量异常的股票：如何实时找到交易量异常的股票</li>
<li>目标达成：第二季度盈利超出预期</li>
<li>突破性股票：它们是什么以及如何识别它们</li>
<li>特斯拉的反弹刚刚开始吗？为什么您应该考虑购买</li>
<li>房地产投资信托基金是否应该在您的投资组合中占一席之地？</li>
<li>斯坦利·德伦米勒的最新押注：MELI—您应该跟随吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA"/></p>
<p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。在发布之前，该故事经过了 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 特朗普正在发出警报（来自 Preserve Gold）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTI3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTI3"/></p>
<h2>现在是否值得投资 1,000 美元在 CRISPR 治疗？</h2>
<p>在考虑投资 CRISPR 治疗之前，您可能想要听听这个。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在购买的股票...而 CRISPR 治疗并不在名单上。</p>
<p>虽然 CRISPR 治疗目前在分析师中有一个 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

CRISPR治疗

<p>Krilogy Financial LLC 在第二季度增加了对 CRISPR Therapeutics AG（NASDAQ:CRSP）的持股比例，增幅达 92.9%，收购了 10,050 股，使其总持股量达到 20,872 股，价值 12.7 万美元。其他机构投资者也增加了他们的持股比例。分析师们提供了不同的目标价格和评级，共识评级为 “持有”，平均目标价格为 66.63 美元。尽管有交易活动，CRISPR 的股票季度每股亏损 0.49 美元，低于预期，因为收入与去年相比显著下降</p>

<p>Krilogy Financial LLC grew its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 92.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 20,872 shares of the company's stock after purchasing an additional 10,050 shares during the period. Krilogy Financial LLC's holdings in CRISPR Therapeutics were worth $1,127,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Krilogy Financial LLC 在第二季度增持了 CRISPR Therapeutics AG（纳斯达克股票代码：CRSP）的持股，增幅达到 92.9%，根据该公司最近向证券交易委员会披露的信息。该公司在该时期购入额外的 10,050 股后，持有该公司股票 20,872 股。Krilogy Financial LLC 在最近一个季度结束时持有的 CRISPR Therapeutics 股票价值 1,127,000 美元。</p>
</div><p>Get <strong>CRISPR Therapeutics</strong> alerts:</p>
<ul>
<li>3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices</li>
</ul>
<div class="lb-trans"><p>获取 <strong>CRISPR Therapeutics</strong> 警报：</p>
<ul>
<li>3 家股价下跌的制药公司，有望迎来价格上涨的催化剂</li>
</ul>
</div><p>A number of other institutional investors also recently modified their holdings of the business. Nordea Investment Management AB grew its holdings in CRISPR Therapeutics by 40.8% during the 1st quarter. Nordea Investment Management AB now owns 148,700 shares of the company's stock valued at $10,305,000 after buying an additional 43,100 shares in the last quarter. Congress Asset Management Co. MA grew its position in shares of CRISPR Therapeutics by 60.3% during the 1st quarter. Congress Asset Management Co. MA now owns 64,605 shares of the company's stock valued at $4,403,000 after purchasing an additional 24,303 shares in the last quarter. PBCay One RSC Ltd bought a new position in shares of CRISPR Therapeutics in the fourth quarter worth $10,329,000. Cetera Investment Advisers increased its stake in CRISPR Therapeutics by 451.3% in the 1st quarter. Cetera Investment Advisers now owns 34,100 shares of the company's stock worth $2,324,000 after acquiring an additional 27,915 shares during the last quarter. Finally, CWM LLC raised its stake in CRISPR Therapeutics by 11,871.1% in the second quarter. CWM LLC now owns 22,386 shares of the company's stock valued at $1,209,000 after purchasing an additional 22,199 shares in the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他许多机构投资者最近也调整了他们对该公司的持股。Nordea Investment Management AB 在第一季度增持了 CRISPR Therapeutics 的持股，增幅为 40.8%。现在，Nordea Investment Management AB 持有该公司 148,700 股，价值 10,305,000 美元，上季度购入了 43,100 股。Congress Asset Management Co. MA 在第一季度增持了 CRISPR Therapeutics 的股份，增幅为 60.3%。现在，Congress Asset Management Co. MA 持有该公司 64,605 股，价值 4,403,000 美元，上季度购入了 24,303 股。PBCay One RSC Ltd 在第四季度购入了价值 10,329,000 美元的 CRISPR Therapeutics 新头寸。Cetera Investment Advisers 在第一季度将其对 CRISPR Therapeutics 的持股增加了 451.3%。Cetera Investment Advisers 现在持有该公司 34,100 股，价值 2,324,000 美元，上季度购入了 27,915 股。最后，CWM LLC 在第二季度将其对 CRISPR Therapeutics 的持股增加了 11,871.1%。CWM LLC 现在持有该公司 22,386 股，价值 1,209,000 美元，上季度购入了 22,199 股。目前，69.20% 的股份由对冲基金和其他机构投资者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>Several analysts have weighed in on the company. Robert W. Baird boosted their price objective on CRISPR Therapeutics from $46.00 to $52.00 and gave the company a &#34;neutral&#34; rating in a research report on Thursday, May 9th. Rodman &amp; Renshaw started coverage on shares of CRISPR Therapeutics in a report on Friday, August 2nd. They issued a &#34;buy&#34; rating and a $90.00 price objective for the company. Needham &amp; Company LLC lowered their target price on CRISPR Therapeutics from $88.00 to $84.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday, August 6th. Barclays reduced their target price on shares of CRISPR Therapeutics from $67.00 to $59.00 and set an &#34;equal weight&#34; rating on the stock in a research report on Tuesday, August 6th. Finally, Guggenheim reiterated a &#34;neutral&#34; rating on shares of CRISPR Therapeutics in a research note on Friday, June 28th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and an average target price of $75.63.</p>
<ul>
<li>Geron Stock Doubles After Imetelstat Receives FDA Panel Approval</li>
</ul>
<div class="lb-trans"><p>一些分析师对该公司发表了意见。Robert W. Baird 将 CRISPR Therapeutics 的价格目标从 46.00 美元提高到 52.00 美元，并在 5 月 9 日星期四的研究报告中给予该公司 “中性” 评级。Rodman &amp; Renshaw 在 8 月 2 日星期五对 CRISPR Therapeutics 的股票进行了覆盖。他们为该公司设定了 “买入” 评级和 90.00 美元的价格目标。Needham &amp; Company LLC 将 CRISPR Therapeutics 的目标价从 88.00 美元降至 84.00 美元，并在 8 月 6 日星期二的研究报告中为该公司设定了 “买入” 评级。巴克莱将 CRISPR Therapeutics 的目标价从 67.00 美元降至 59.00 美元，并在 8 月 6 日星期二的研究报告中为该股设定了 “等权重” 评级。最后，Guggenheim 在 6 月 28 日星期五的研究报告中重申了对 CRISPR Therapeutics 的 “中性” 评级。三位股票研究分析师给予该股 “卖出” 评级，八位给予 “持有” 评级，九位给予 “买入” 评级。根据 MarketBeat.com 的数据，该股目前的共识评级为 “持有”，平均目标价为 75.63 美元。</p>
</div><p><strong>Read Our Latest Analysis on CRSP</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 CRSP 的最新分析</strong></p>
</div><h2>CRISPR Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>CRISPR Therapeutics 股价表现</h2>
</div><p>Shares of CRSP traded up $0.92 during trading hours on Wednesday, hitting $49.99. The stock had a trading volume of 1,108,313 shares, compared to its average volume of 1,573,917. The firm has a market capitalization of $4.25 billion, a PE ratio of -18.17 and a beta of 1.70. The stock has a fifty day moving average price of $55.02 and a 200 day moving average price of $61.96. CRISPR Therapeutics AG has a 12 month low of $37.55 and a 12 month high of $91.10.</p>
<ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><p>CRSP 股票周三交易时上涨 0.92 美元，报价 49.99 美元。该股交易量为 1,108,313 股，相比平均交易量 1,573,917 股有所下降。该公司的市值为 42.5 亿美元，市盈率为-18.17，贝塔系数为 1.70。该股的五十日移动平均价格为 55.02 美元，两百日移动平均价格为 61.96 美元。CRISPR Therapeutics AG 的 52 周最低价为 37.55 美元，最高价为 91.10 美元。</p>
</div><p>CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The business had revenue of $0.52 million during the quarter, compared to analyst estimates of $12.31 million. During the same period in the previous year, the company earned ($0.98) earnings per share. The business's revenue for the quarter was down 99.3% compared to the same quarter last year. As a group, analysts anticipate that CRISPR Therapeutics AG will post -5.52 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>CRISPR Therapeutics（纳斯达克股票代码：CRSP - 获取免费报告）于 8 月 5 日星期一发布了季度财报。该公司报告称，该季度每股收益（EPS）为-1.49 美元，低于市场预期的-1.43 美元。该季度业务收入为 520 万美元，而分析师预计为 12.31 亿美元。与去年同期相比，该季度业务收入下降了 99.3%。分析师预计，CRISPR Therapeutics AG 在本财年将实现-5.52 美元的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部人员活动</h2>
</div><p>In other news, COO Julianne Bruno sold 3,366 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the sale, the chief operating officer now owns 6,745 shares in the company, valued at $378,327.05. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 4.10% of the company's stock.</p>
<div class="lb-trans"><p>另外，首席运营官 Julianne Bruno 于 6 月 21 日星期五出售了 3,366 股 CRISPR Therapeutics 股票。这些股票的平均价格为 56.09 美元，总交易额为 188,798.94 美元。在此次交易后，首席运营官现在持有公司 6,745 股，价值 378,327.05 美元。该交易已在提交给证券交易委员会的文件中披露，可在此链接处查看。内部人员持有该公司的股份占公司股份的 4.10%。</p>
</div><h2>CRISPR Therapeutics Profile (Free Report)</h2>
<div class="lb-trans"><h2>CRISPR Therapeutics 简介（免费报告）</h2>
</div><p>CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.</p>
<div class="lb-trans"><p>CRISPR Therapeutics 是一家专注于利用其专有的 CRISPR/Cas9 平台开发用于治疗严重疾病的转型基因药物的基因编辑公司。CRISPR/Cas9 是一种革命性的基因编辑技术，可以对基因组 DNA 进行精确、定向的改变。CRISPR Therapeutics 已在包括血红蛋白病、肿瘤学、再生医学和罕见疾病在内的广泛疾病领域建立了治疗项目组合。</p>
</div><h2>See Also</h2>
<ul>
<li>Five stocks we like better than CRISPR Therapeutics</li>
<li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li>
<li>Target Hits the Mark: Q2 Earnings Exceed Expectations</li>
<li>Breakout Stocks: What They Are and How to Identify Them</li>
<li>Is Tesla’s Rebound Just Starting? Why You Should Consider Buying</li>
<li>Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?</li>
<li>Stanley Druckenmiller's Latest Bet: MELI—Should You Follow Suit?</li>
</ul>
<div class="lb-trans"><h2>另请参阅</h2>
<ul>
<li>我们喜欢的五只股票，比 CRISPR Therapeutics 更好</li>
<li>交易量异常的股票：如何实时找到交易量异常的股票</li>
<li>目标达成：第二季度盈利超出预期</li>
<li>突破性股票：它们是什么以及如何识别它们</li>
<li>特斯拉的反弹刚刚开始吗？为什么您应该考虑购买</li>
<li>房地产投资信托基金是否应该在您的投资组合中占一席之地？</li>
<li>斯坦利·德伦米勒的最新押注：MELI—您应该跟随吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CRSP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。在发布之前，该故事经过了 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ Trump is sounding the alarm (From Preserve Gold)(Ad)</p>
<div class="lb-trans"><p>→ 特朗普正在发出警报（来自 Preserve Gold）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTI3" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8927&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in CRISPR Therapeutics right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1,000 美元在 CRISPR 治疗？</h2>
</div><p>Before you consider CRISPR Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 CRISPR 治疗之前，您可能想要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在购买的股票...而 CRISPR 治疗并不在名单上。</p>
</div><p>While CRISPR Therapeutics currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CRISPR 治疗目前在分析师中有一个 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Krilogy Financial LLC 收购了 CRISPR 治疗公司（纳斯达克股票代码：CRSP）的 10,050 股股票